Ezobresib
Overview of the drug Ezobresib
| Ezobresib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Ezobresib is a small molecule inhibitor that targets the bromodomain and extraterminal domain (BET) family of proteins. It is primarily investigated for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit | edit source]
Ezobresib functions by inhibiting the BET family of proteins, which includes BRD2, BRD3, BRD4, and BRDT. These proteins are involved in regulating gene expression by binding to acetylated lysines on histone tails, thereby influencing chromatin structure and function. By inhibiting these interactions, Ezobresib can disrupt the expression of genes that are critical for cancer cell growth and survival.
Pharmacology[edit | edit source]
Ezobresib is administered orally and has been shown to have a favorable pharmacokinetic profile. It is absorbed into the bloodstream and distributed throughout the body, where it exerts its effects on BET proteins. The drug is metabolized primarily in the liver and excreted through the kidneys.
Clinical Development[edit | edit source]
Ezobresib is currently undergoing clinical trials to evaluate its efficacy and safety in treating various malignancies, including hematological cancers and solid tumors. Early-phase trials have demonstrated promising results, with some patients experiencing significant tumor reduction.
Potential Side Effects[edit | edit source]
As with many cancer therapies, Ezobresib may cause side effects. Commonly reported adverse effects include fatigue, nausea, and decreased blood cell counts. More serious side effects can occur, and patients are monitored closely during treatment.
Research and Future Directions[edit | edit source]
Ongoing research is focused on understanding the full potential of Ezobresib in cancer therapy. Studies are exploring its use in combination with other anticancer agents to enhance therapeutic outcomes. Additionally, research is being conducted to identify biomarkers that can predict patient response to Ezobresib.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
